{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:25:05Z","timestamp":1787934305955,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2023.02.012","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T06:54:15Z","timestamp":1677999255000},"page":"367-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["When triple therapy is not working: A reverse iceberg perspective"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-0963","authenticated-orcid":false,"given":"Carlo","family":"Castellani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.02.012_bib0001","doi-asserted-by":"crossref","unstructured":"Southern K.W., Castellani C., Lammertyn E., Smyth A., VanDevanter D., van Koningsbruggen-Rietschelet S., et\u00a0al. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. Published online: 2022. DOI:10.1016\/j.jcf.2022.10.002.","DOI":"10.1016\/j.jcf.2022.10.002"},{"issue":"5","key":"10.1016\/j.jcf.2023.02.012_bib0002","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"issue":"6","key":"10.1016\/j.jcf.2023.02.012_bib0003","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR-modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2023.02.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221108627","article-title":"Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?","volume":"13","author":"Niedermayr","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"19","key":"10.1016\/j.jcf.2023.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.02.012_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2023.02.012_bib0007","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2023.02.012_bib0008","article-title":"Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis","author":"Nichols","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.02.012_bib0009","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1513\/AnnalsATS.202102-220RL","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in advanced cystic fibrosis lung disease","volume":"18","author":"Djavid","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2023.02.012_bib0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","article-title":"Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor","volume":"14","author":"Siracusa","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.02.012_bib0011","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/humu.23389","article-title":"Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules","volume":"39","author":"Baatallah","year":"2018","journal-title":"Hum Mutat"},{"issue":"18","key":"10.1016\/j.jcf.2023.02.012_bib0012","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.3390\/ijms231810377","article-title":"Evaluation of the complex p.[Leu467Phe;Phe508del] CFTR allele in the intestinal organoids model: implications for therapy","volume":"23","author":"Kondratyeva","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.jcf.2023.02.012_bib0013","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12864-022-08466-z","article-title":"High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients","volume":"23","author":"Petrova","year":"2022","journal-title":"BMC Genomics"},{"issue":"22","key":"10.1016\/j.jcf.2023.02.012_bib0014","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.3390\/ijms232214205","article-title":"Modifier factors of cystic fibrosis phenotypes: a focus on modifier genes","volume":"23","author":"M\u00e9sin\u00e8le","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2023.02.012_bib0015","doi-asserted-by":"crossref","first-page":"13064","DOI":"10.3390\/ijms222313064","article-title":"Synergy in cystic fibrosis therapies: targeting SLC26A9","volume":"22","author":"Pinto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2023.02.012_bib0016","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2021.04.013","article-title":"Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors","volume":"20","author":"Saint-Criq","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.02.012_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcf.2016.11.008","article-title":"Biological variability of the sweat chloride in diagnostic sweat tests: a retrospective analysis","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.02.012_bib0018","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:49:17Z","timestamp":1761601757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199323000632"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.02.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When triple therapy is not working: A reverse iceberg perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}